Oxford Pharmascience Group Plc | Medicines made better

 

Scientific Advisory Board

The management team is supported by a Scientific Advisory Board of independent world class experts in medical and clinical science as well as pharmaceutical research and technologies.

Professor Bill Dawson

Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.

Professor Kim Rainsford, PhD, FRCPEdin, FRCPath, FRSC, CSci, FSB, FIBMS, Dr(hc), Emeritus Professor of Biomedical Sciences Sheffield Hallam University, Sheffield, UK

Professor Rainsford has over 40 years research experience principally on the modes of action and adverse reactions of anti-inflammatory agents used to treat pain, arthritis and other inflammatory diseases. He has focussed on procedures for reducing the serious adverse side-effects (e.g. gastro-intestinal ulceration) from anti-inflammatory/analgesic drugs. His publications include 202 original research papers, 26 books, 82 reviews and he has given 145 invited or contributed presentations at international conferences. He is Editor-in-Chief of the international interdisciplinary journal, Inflammopharmacology, Associate Editor - Clinical & Experimental Pharmacology of Journal of Pharmacy and Pharmacology, member of the Editorial Board of Inflammation Research, and organiser of the Inflammopharmacology international conference series.

Professor Ingvar Bjarnason

Practicing at BUPA Cromwell Hospital and King's College Hospital, Professor Ingvar Bjarnason has been recognised as one of the top gastroenterologists in the UK. His research contributions include over 300 peer reviewed papers and book chapters and these mainly address the interaction between intestinal integrity, permeability and inflammation as well as new treatments of IBD. His main scientific contributions relate to the original description of NSAID-induced enteropathy in man, its pathogenesis and treatment.

Doctor Michael Khan

Dr. Michael Khan BSC, MBBS, PhD, FRCP is Associate Professor of Medicine, Former Head of Molecular Medicine at the Biomedical Research Institute, University of Warwick School of Life Sciences and Consultant Physician, Director of the County Familial Hypercholesterolaemia, Lipid and Coronary Prevention Clinics at University Hospitals of Coventry and Warwickshire NHS Trust and Warwick Institute for Study of Diabetes, Endocrinology and Metabolism (WISDEM).

Dr. Nigel Capps, Specialist Advisor to Statins Programme

Consultant Chemical Pathologist and Director of Research & Development, The Shrewsbury & Telford Hospital NHS Trust, Clinical Director and Joint Cardiovascular Speciality Group Lead, West Midlands North Comprehensive Local Research Network. Chair, Medical Scientific & Research Committee, HEART UK The Cholesterol Charity.